FRESENIUS SE+CO.KGAA O.N.
Commented by Carsten Mainitz on October 14th, 2026 | 05:25 CEST
Who Profits When Patents Expire? The Billion-Euro Race Between Formycon, Fresenius and Pfizer
When patent protection for high-revenue biopharmaceuticals expires, a billion-euro market for follow-on products emerges. Michael Sen, head of the German healthcare group Fresenius SE, cites an impressive figure. By 2035, this could generate around EUR 180 billion in revenue. In particular, biosimilars, biotechnologically produced follow-on medicines that are highly similar in composition to the original medicine and equivalent in quality, efficacy and safety, are forecast to grow significantly. Moreover, biosimilars can strengthen competition and reduce treatment costs. Formycon stands out as a pure play. The company recently reached a crucial milestone. The US Food and Drug Administration (FDA) accepted the marketing authorisation application, the first publicly known application of its kind, for FYB206, a biosimilar candidate to the cancer medicine Keytruda, for review. Keytruda generates around USD 32 billion in annual revenue, making it the world's highest-revenue medicine. Fresenius is strengthening its positioning in the biosimilar sector through an acquisition. Pfizer needs new growth drivers. Who is best positioned for the year-end rally?
Read
Commented by Nico Popp on August 2nd, 2022 | 10:57 CEST
These sources of return concern us all: Fresenius, Defence Therapeutics, BioNTech
When people receive an unexpected diagnosis or a loved one suddenly dies, our health suddenly becomes very important. Even though there is often no room for such topics in the daily lives of investors, it is worthwhile to deal with health for several reasons. On the one hand, preventive care brings the most important of all returns; on the other hand, this rather unpleasant topic in everyday life also holds opportunities if we focus on health risks and look at possible solutions. We present three stocks from the healthcare sector that deserve attention.
Read
Commented by André Will-Laudien on September 16th, 2021 | 11:58 CEST
Siemens Healthineers, PuriflOH, Fresenius, Novavax - Focusing on health!
The pandemic outbreak in 2020 ushered in a new era. People's health is once again moving to the center of attention. Politicians worldwide see themselves obligated to make public life safe, but whether this will be 100% successful remains questionable. Ultimately, it will depend on the commitment of private companies to what extent the existing health issues can be solved and by what means. On the capital markets, the healthcare sector has been sailing on the highest wave for months because the dangers for billions of people need to be reduced, and framework conditions for public life need to be created. Who benefits the most?
Read
Commented by Carsten Mainitz on March 17th, 2021 | 07:30 CET
Royal Dutch Shell, Pollux Properties, Fresenius SE - Value stocks with some catching up to do!
Last year's Corona shock initially sent almost all shares into a tailspin. While some were able to recover relatively quickly and in some cases started massive price rallies, so-called value stocks had a hard time. Now, the rotation towards value stocks has partially begun. In the following, we will show you 3 stocks where you can still make a bargain. Seize the opportunity!
Read
Commented by Nico Popp on March 17th, 2021 | 07:25 CET
Fresenius SE, Q+M Dental Group, Siemens Healthineers: Where growth meets dividends
The back-and-forth surrounding AstraZeneca's vaccine has unsettled many people. But the discussion about extremely rare side effects also shows: Vaccines and drugs are subject to strict regulations and the healthcare system is strictly regulated. While pharmaceutical companies must always expect setbacks, especially in accelerated approval procedures, the situation is different for suppliers of medical technology or consumables. We present three stocks that are benefiting from rising healthcare spending.
Read
Commented by Nico Popp on February 8th, 2021 | 07:30 CET
Fresenius, Fresenius Medical Care, Q&M Dental: Healthy returns await here
Healthcare stocks have been in demand not just since the pandemic, but the pandemic is a sure game-changer for the industry in the long term. Demand for consumables and tests will continue to rise because this much seems certain: the Coronavirus will remain with us and possibly return year after year like a wave of influenza. Companies in the industry can profit from this. We present three stocks.
Read
Commented by André Will-Laudien on January 28th, 2021 | 10:39 CET
Fresenius - Q&M Dental Group - IBU-tec: New price explosions every day!
Rarely has the stock market been so volatile and exciting as in the last few days. Hedge fund Melvin Capital had to close out because of the GameStop share, and now the next wave is probably looming with AMC Entertainment. A full 270% went through the roof right at the opening; according to the New York Stock Exchange (NYSE) thousands of buy orders were already there at opening. Again, there had been a recommendation in a social media channel. On the Nasdaq, it jumped rapidly from USD 5 to USD 21 right at the opening - something you rarely see. And GameStop continues today after yesterday's debacle! After several trading suspensions, the value exploded further from USD 149 to USD 380 after a good hour of trading. That should have been the end of trading school for many new entrants!
Read
Commented by Mario Hose on January 15th, 2020 | 07:42 CET
Fresenius Peer: Will the analysts' favorite M1 Kliniken 2020 take off?
Besides Fresenius, M1 Klinken AG is one of the few listed clinic operators in Germany. Unlike the clinic group, M1 has specialised in a lucrative niche: the beauty market. More and more people are helping with beauty and are generating billions in sales in the industry. In just a few years, M1 has become the market leader for beauty medicine in Germany. A growth rate of 30% is also targeted for the future. Foreign business is increasingly becoming the growth driver. After a continuous price increase between 2016 and 2018, the share has consolidated in 2019. But operationally things are still running smoothly. Analysts see more than 50% upside potential.
Read